• Ar
  • Es
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Feature
  • Videos
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Feature
Videos
Infographs
In Pictures
  1. Home
  2. News
  3. US & Canada
  4. US drugmaker Eli Lilly makes insulin more affordable, slashes prices
US & Canada

US drugmaker Eli Lilly makes insulin more affordable, slashes prices

  • By Al Mayadeen English
  • Source: Agencies
  • 2 Mar 11:53

United States-based drugmaker Eli Lilly slashed the costs of insulin as the country faces a problem that has become a cause célèbre.

  • Photo shows a vial of Eli Lilly's Humalog insulin in New York (AP).
    Photo shows a vial of Eli Lilly's Humalog insulin in New York, US (AP).

As drug prices soar in the US, pharmaceutical company Eli Lilly and Company, based in Indianapolis, Indiana, announced, on Wednesday, that it would slash insulin costs by about 70%.

US President Joe Biden called on other pharmaceutical companies to follow in Lilly's footsteps and cut the costs of insulin following years of large-scale profits.

In a statement, Biden said "Insulin costs less than $10 to make, but Americans are sometimes forced to pay over $300 for it. It's flat wrong," adding that Lilly's announcement is "huge news" as he urged others to follow.

Lilly announced a variety of price-cutting measures, which included the capping of out-of-pocket expenditures for customers with insurance at $35 per month.

In a statement, the company said "Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system."

It is worth noting that although the $35 cap goes into effect immediately, the remaining measures will be phased in over the course of 2023.

The price reduction of Humalog, Lilly's most widely prescribed insulin, is a game-changer. 

According to the US Centers for Disease Control and Prevention, the prevalence of diabetes in adults has more than quadrupled in the previous 20 years, affecting 37.3 million individuals. 

We capped the cost of insulin for seniors on Medicare at $35.

But in my State of the Union, I said we needed to finish the job.

Well, today, Eli Lilly announced that they’re lowering prices for everyone else to $35.

Let’s keep it going. pic.twitter.com/XXBXe4HnR4

— President Biden (@POTUS) March 1, 2023

Moreover, according to a 2020 Rand Corporation report, insulin prices in the US are more than eight times higher than in 32 similar high-income nations.

Until now, much of the benefit from exorbitant drug prices goes to insurers in the form of rebates rather than to pharmaceutical companies. As a result, the financial impact of Lilly's move may fall largely on insurers.

Insulin's high cost, particularly for uninsured individuals, has become a cause célèbre for pharmaceutical industry critics. 

Senator Bernie Sanders criticized the pharma industry as emblematic of "unacceptable corporate greed."

In a Twitter post, Sanders said, "At a time when Eli Lilly made over $7 billion in profits last year, public pressure forced them to reduce the price of insulin by 70%," adding that "Sanofi and Novo Nordisk must do the same."

This is what fighting back accomplishes: At a time when Eli Lilly made over $7 billion in profits last year, public pressure forced them to reduce the price of insulin by 70%. Sanofi and Novo Nordisk must do the same. https://t.co/0UtawajURk

— Bernie Sanders (@SenSanders) March 1, 2023

On this note, both Sanofi and Novo Nordisk issued statements to AFP referring to efforts designed to make insulin more accessible, particularly for uninsured patients.

Eli Lilly Chief Executive David Ricks, in a statement, encouraged drugmakers across the US to join efforts in making insulin more accessible to everybody.

Ricks noted, "We know that 7 out of 10 Americans don't use Lilly insulin. We are calling on policymakers, employers and others to join us in making insulin more affordable."

Read more: Trikafta, an inaccessible medical 'miracle': NYT

  • Insulin
  • Medicare
  • US
  • pharmaceuticals
  • Eli Lilly

Trending Now

All
Photo by The Daily Mail

DNA mutation from spaceflight may increase cancer risk in astronauts

Most Read

US dollar may lose status as global reserve currency: Yellen

US dollar may lose status as global reserve currency: Yellen

  • US & Canada
  • 22 Mar
Ukrainian President Volodymyr Zelensky speaks at a press conference on 25, February, 2022. (AFP)

Kiev unable to launch counteroffensive: Zelensky

  • Europe
  • 25 Mar
Europe's move has only increased Putin’s esteem outside the West -- but estimation of Europe’s political nous and understanding of Russia, however, is sharply diminished.

Lawfare Comes into Fashion: The New Geo-political ‘Rack’

  • Analysis
  • 25 Mar
Crewmen enter Bradley fighting vehicles at a US military base at an undisclosed location in Northeastern Syria, on November 11, 2019 (AP)

US occupation bases under fire in Syria for second day in a row

  • MENA
  • 24 Mar

Read this

All
Mounted police disperse anti-government protesters in 'Tel Aviv', occupied Palestine, March 27, 2023 (AP)
US & Canada

IOF separating protesters, Netanyahu supporters to curb clashes

  • 28 Mar
File photo of United Nations Security Council meeting. (AFP)
Europe

UNSC fails to adopt Russian draft calling for Nord Stream probe

  • 28 Mar
.
Palestine

Report shows settlers' trust in Israeli institutions hits record low

  • Today
Ukrainian soldiers ride atop a British-supplied APC on the frontline in Bakhmut, Donetsk region, Sunday, March 26, 2023 (AP Photo/Libkos)
Europe

Biden to escalate in Ukraine: NYT

  • 28 Mar
Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS